43 completed, 9 recruiting, 6 terminated, 5 active not recruiting. 68 Phase 1, 23 Phase 2.
Follow Thrombocythemia, Essential: new trials by email Literature Review of Thrombocythemia, Essential trials Research Report on Thrombocythemia, Essential
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms DMR-001, Ruxolitinib - Myeloproliferative Neoplasms (MPNs) | Phase 1 | Recruiting | Damora Therapeutics | 250 | 2026-09-01 | 2026-10-27 |
| Study of INCA036978 in Participants With Myeloproliferative Neoplasms INCA036978, Standard disease-directed therapy - Myeloproliferative Neoplasms | Phase 1 | Recruiting | Incyte Corporation | 218 | 2026-05-11 | 2026-11-13 |
| Safety and Tolerability of ZE74-0282 in Healthy Volunteers ZE74-0282-0001 or placebo - Healthy Volunteers | Phase 1 | Recruiting | Eilean Therapeutics AU Pty Ltd | 64 | 2026-04-16 | 2026-07-28 |
| A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms INCA035784 - Myeloproliferative Neoplasms | Phase 1 | Recruiting | Incyte Corporation | 120 | 2025-10-01 | 2026-08-06 |
| Study to Assess Safety and Preliminary Efficacy of Orally Administered JBI-802 in Subjects With Essential Thrombocythemia (ET) and Polycythemia Vera (PV) With Thrombocytosis JBI-802 - Essential Thrombocythemia (ET), Polycythemia Vera | Phase 1 / Phase 2 | Recruiting | Jubilant Therapeutics Inc. | 70 | 2024-10-21 | 2026-11-17 |
| A Study of GLB-001 in Patients With Myeloid Malignancies GLB-001 - Polycythemia Vera, Essential Thrombocythemia | Phase 1 | Recruiting | Hangzhou GluBio Pharmaceutical Co., Ltd. | 108 | 2024-05-24 | 2025-08-19 |
| Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition Talazoparib, pacritinib - Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 1 | Recruiting | Fox Chase Cancer Center | 24 | 2024-04-05 | 2024-05-03 |
| A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms INCA033989, Ruxolitinib - Myeloproliferative Neoplasms | Phase 1 | Recruiting | Incyte Corporation | 290 | 2023-12-04 | 2026-04-17 |
| A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms INCA033989, Ruxolitinib - Myeloproliferative Neoplasms | Phase 1 | Active not recruiting | Incyte Corporation | 160 | 2023-09-25 | 2026-08-10 |
| Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm Peptide-based vaccine, Poly ICLC - Myelofibrosis, Essential Thrombocythemia | Phase 1 | Active not recruiting | Marina Kremyanskaya | 7 | 2023-04-04 | 2026-09-28 |
| An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms N-Acetylcysteine - Myeloproliferative Neoplasm, MPN | Phase 1 / Phase 2 | Recruiting | University of California, Irvine | 27 | 2022-01-03 | 2026-03-10 |
| Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms INCB057643, Ruxolitinib - Myelofibrosis, Myelodysplastic Syndrome | Phase 1 | Active not recruiting | Incyte Corporation | 140 | 2021-02-23 | 2026-04-01 |
| A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms TAS1553 - Acute Myeloid Leukemia, Myeloproliferative Neoplasm | Phase 1 | Terminated | Astex Pharmaceuticals, Inc. | 20 | 2020-12-21 | 2024-08-02 |
| Study of Select Combinations in Adults With Myelofibrosis MBG453, NIS793, Spartalizumab - Primary Myelofibrosis, Myelofibrosis | Phase 1 | Withdrawn | Novartis Pharmaceuticals | 2020-11-30 | 2021-03-04 | |
| A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm Navitoclax, Ruxolitinib, Celecoxib - Myeloproliferative Neoplasm | Phase 1 | Active not recruiting | AbbVie | 85 | 2019-11-08 | 2025-02-14 |
| Dual Vaccine Trial in Myeloproliferative Neoplasms PD-L1 peptide: PD-L1 Long(19-27) Peptide sequence: FMTYWHLLNAFTVTVPKDL, Arginase1 peptide: ArgLong2(169-206) Peptide sequence ISAKDIVYIGLRDVDPGEHYILKTLGIKYFSMTEVDRL - Polycythemia Vera, Essential Thrombocythemia | Phase 1 / Phase 2 | Completed | Inge Marie Svane | 9 | 2019-07-10 | 2023-07-13 |
| Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Azacitidine, Pevonedistat, Venetoclax - Acute Myeloid Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 40 | 2019-02-27 | 2026-07-16 |
| Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms Allogeneic Hematopoietic Stem Cell Transplantation, Liposome-encapsulated Daunorubicin-Cytarabine, Ruxolitinib - Essential Thrombocythemia, Myelofibrosis | Phase 1 / Phase 2 | Terminated | Ohio State University Comprehensive Cancer Center | 12 | 2019-02-20 | 2026-04-24 |
| CALR Exon 9 Mutant Peptide Vaccine to Patients With CALR-mutant Myeloproliferative Neoplasms CALRLong36 peptide - Myeloproliferative Neoplasm, Unclassifiable, Essential Thrombocythemia | Phase 1 | Completed | Inge Marie Svane | 10 | 2018-06-20 | 2023-07-13 |
| Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia RG7388, Pegasys - Polycythemia Vera, Essential Thrombocythemia | Phase 1 | Completed | John Mascarenhas | 13 | 2015-04-01 | 2019-09-12 |
Showing 20 of 68. Sign in to see all of them.
Primary Myelofibrosis (61) · Polycythemia Vera (56) · Myeloproliferative Disorders (54) · Leukemia, Myeloid, Acute (39) · Leukemia, Myelomonocytic, Chronic (34) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (33) · Myelodysplastic Syndromes (32) · Leukemia, Lymphocytic, Chronic, B-Cell (29) · Leukemia (28) · Burkitt Lymphoma (26) · Lymphoma, Follicular (26) · Lymphoma, Mantle-Cell (26) · Lymphoma, B-Cell, Marginal Zone (25) · Lymphoma, Large B-Cell, Diffuse (25)
Hemic and Lymphatic Diseases (68) · Blood Coagulation Disorders (67) · Blood Platelet Disorders (67) · Hemorrhagic Disorders (67) · Bone Marrow Diseases (65) · Hematologic Diseases (65) · Thrombocytosis (65) · Neoplasms (57) · Neoplasms by Site (57) · Bone Marrow Neoplasms (56) · Hematologic Neoplasms (55) · Disease Attributes (43) · Leukemia, Myeloid (43) · Neoplasms by Histologic Type (43) · Pathologic Processes (43)
Peripheral Blood Stem Cell Transplantation (9) · ruxolitinib (9) · Cyclophosphamide (6) · Cyclosporine (6) · fludarabine phosphate (5) · Antilymphocyte Serum (4) · Busulfan (4) · Decitabine (4) · Filgrastim (4) · Methotrexate (4) · Carboplatin (3) · Cytarabine (3) · Etoposide (3) · Methylprednisolone (3) · Tacrolimus (3)
National Cancer Institute (NCI) (7) · Incyte Corporation (5) · Fred Hutchinson Cancer Center (4) · Eli Lilly and Company (3) · California Cancer Consortium (2) · Inge Marie Svane (2) · M.D. Anderson Cancer Center (2) · Mayo Clinic (2) · Northwestern University (2) · Novartis Pharmaceuticals (2) · AbbVie (1) · Alliance for Clinical Trials in Oncology (1) · Asan Medical Center (1) · Astex Pharmaceuticals, Inc. (1) · BioCryst Pharmaceuticals (1)
United States (56) · Australia (8) · Italy (8) · Germany (7) · United Kingdom (7) · Canada (6) · France (6) · Belgium (5) · Spain (5) · Denmark (4) · Japan (4) · China (2) · Netherlands (2) · Poland (2) · South Korea (2)
Jacob H Grauslund, MD (2) · Jorge Cortes, MD (2) · Richard K. Burt, MD (2) · Ronald Hoffman, MD (2) · Todd M. Zimmerman, MD (2) · Alex Shalaurov, MD, PhD (1) · Andrew Roberts, M.D. (1) · Angela Fleischman, MD, PhD (1) · Ann E. Woolfrey, MD (1) · Ann Mohrbacher, MD (1) · Aref Al-Kali (1)
PMID 15570084, PMID 22259028, PMID 24474568, PMID 25563429, PMID 25762180, PMID 26210442, PMID 26853648, PMID 27479177, PMID 28934680, PMID 30562587, PMID 31167802, PMID 32634234, PMID 33718228, PMID 36881782, PMID 36911725, PMID 37422688, PMID 37530627, PMID 38259250
2018 (2), P30CA015083 (2), U01CA062491 (2), 2019 (1), 2023 (1), P01CA018029 (1), P01CA108671 (1), P30CA006973 (1), P30CA016058 (1), P30CA016086 (1), P30CA016087 (1), P30CA023074 (1), P30CA033572 (1), P30CA036727 (1), P30CA072720 (1)